2nd July 2019 Product update: rapidmicrobiology staff writer
NeuMoDx™ Launches CE-IVD Asaays for HBV & HCV
NeuMoDx™ Molecular has launched CE-IVD assays for Hepatitis B virus (HBV) and Hepatitis C virus (HCV).
Hepatitis infections are more frequent in immunocompromised populations than in the general population with lower rates of spontaneous recovery in acute cases, thus resulting in increased morbidity and mortality in these patients. Quantitation of HBV DNA and HCV RNA titers in infected patients is essential to monitor disease progression and efficacy of antiviral therapies, as well as to aid in the management of patients with HCV or HBV infections.
In addition to focusing design and development efforts on tests to detect Sexually Transmitted and Infectious Diseases, NeuMoDx™ molecular offers solutions that integrate the entire molecular diagnostic process – from extraction to detection or ‘sample to result’ – with the first result available in approximately one hour. These innovative analyzers provide operators with the ability to load patient samples in a continuous, random-access workflow resulting in on-demand, high throughput sample processing with a true operator walkaway window of up to eight hours.
The proprietary NeuDry™ reagents used with the systems require no refrigeration and are extremely robust with an on-board stability of up to 60 days and ambient temperature shelf life of greater than one year.
Furthermore, the unitized format of the NeuDry™ reagents significantly increases operating efficiency while minimizing the waste associated with systems requiring manual reconstitution and use of bulk format lyophilized reagents. In addition, NeuMoDx™ offers a broad range of general-purpose reagents and consumables for use by customers in developing qualitative and quantitative Laboratory Developed Tests (LDTs) for use with the NeuMoDx™ systems to detect and amplify DNA and RNA targets.
Date Published: 2nd July 2019
Source article link: https://www.neumodx.com/neumodx-launches-ce-ivd-assays-for-hbv-hcv/
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.